Is Biomm SA halal to invest in?

As of September 2026, Biomm SA BIOM3.SA is classified as not covered according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Biomm SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biomm SA using these criteria to determine its compliance status.

Can Muslims buy shares of Biomm SA?

Muslim investors may consider investing in Biomm SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Biomm SA classified as NOT COVERED?

Musaffa determines the Shariah status of Biomm SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Biomm SA updated?

The Shariah compliance status of Biomm SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Biomm SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Biomm SA?

You can check the latest Shariah compliance status of Biomm SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Biomm SA. Stock Analysis BIOM3.SA

Brazil Health Care Micro Cap

BIOMM SA engages in the research, development, and manufacture of insulin. The company is headquartered in Nova Lima, Minas Gerais. The company went IPO on 2002-09-05. The firm is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Company’s technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Company’s technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Company’s subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.

Biomm SA BIOM3.SA

Last Updated: Sep 11, 12:00 AM·BOVESPA